10.03.12
ICON plc, and Korea National Enterprise for Clinical Trials (KoNECT) have partnered to advance clinical trials in South Korea. ICON and KoNECT will collaborate on a series of educational events for local and multinational pharma companies, investigators and industry officials. The program aims to enhance current high standards of clinical research in South Korea and will begin with an oncology trials seminar in Seoul on October 26th.
“South Korea has become a key country for clinical development and ICON has had a well-established presence there since 2005,” said Wei Ming Goh, ICON’s vice president, Asia-Pacific. “Our agreement with KoNECT supports our mutual interest in developing and growing the clinical research industry in South Korea and demonstrates our on-going commitment to the Asia Pacific region.”
KoNECT president, professor Sang-Goo Shin, said, “We are delighted to collaborate with a leading CRO such as ICON that has a wealth of expertise in both local and global clinical development programs. Together we can develop high quality clinical research professionals and a clinical trials infrastructure that can support the increased demand from local and global pharma companies.”
“South Korea has become a key country for clinical development and ICON has had a well-established presence there since 2005,” said Wei Ming Goh, ICON’s vice president, Asia-Pacific. “Our agreement with KoNECT supports our mutual interest in developing and growing the clinical research industry in South Korea and demonstrates our on-going commitment to the Asia Pacific region.”
KoNECT president, professor Sang-Goo Shin, said, “We are delighted to collaborate with a leading CRO such as ICON that has a wealth of expertise in both local and global clinical development programs. Together we can develop high quality clinical research professionals and a clinical trials infrastructure that can support the increased demand from local and global pharma companies.”
